Learn how PET and PET-CT scans detect cancer at the cellular level, what FDG tracer does, and how to prepare with fasting for accurate metabolic imaging.
Your Complete Guide to PET & PET-CT Scans
At a glance
- PET scans use a radioactive glucose tracer to detect cellular metabolic activity, making them powerful tools for finding cancer, inflammation, and brain disorders.
- When combined with CT, a PET-CT scan provides both functional and anatomical images, showing exactly where abnormal activity is located in the body.
- Strict fasting for 6 hours and a low-carbohydrate diet are essential for accurate results, as high blood sugar competes with the tracer.
- The radiotracer leaves your body naturally through urine within 6 to 24 hours, and drinking water accelerates this process.
- PET-CT scans deliver a moderate radiation dose, but the clinical benefit of early and accurate cancer detection far outweighs the small risk.
A PET scan is one of the most powerful tools in modern medicine for detecting diseases at the cellular level. Unlike other imaging tests that show the structure of your organs, a Positron Emission Tomography scan reveals how your cells are functioning. It can spot cancer, measure brain activity, and evaluate heart disease by tracking how your body uses glucose, the primary fuel for most cells.
When doctors combine PET with a CT scan, they create a PET-CT scan — a single test that shows both metabolic activity and detailed anatomy. This dual approach helps doctors pinpoint exactly where abnormal cells are hiding, how aggressive a tumor might be, and whether treatment is working. Over 2 million PET-CT scans are performed annually in the United States, making it an indispensable tool in oncology, neurology, and cardiology.
Did you know? The most common tracer used in PET scans is called FDG — fluorodeoxyglucose. It is essentially a sugar molecule with a tiny radioactive tag. Because cancer cells consume sugar up to 200 times faster than normal cells, they light up like beacons on a PET scan.
🔬 Elevate Your Department's Imaging Standards
Access premium interventional radiology consumables and safety solutions designed for modern nuclear medicine and oncology suites.
Explore SATMED Health Solutions →How PET scans detect cellular activity
A PET scan works by introducing a tiny amount of radioactive tracer into your bloodstream, usually through an intravenous (IV) line in your arm. The tracer is chemically identical to glucose, the sugar your cells use for energy. Once injected, the tracer travels through your bloodstream and is absorbed by cells throughout your body.
Here is the key principle: cells that are more active absorb more glucose. Cancer cells, which multiply rapidly, are extremely hungry for sugar. They pull in the radioactive tracer at much higher rates than surrounding healthy tissue. The PET scanner detects the radiation emitted by the tracer and creates a three-dimensional map showing where the tracer has concentrated.
Why glucose is the perfect tracer
Most cells in your body use glucose as their primary fuel source. This makes glucose-based tracers like FDG incredibly versatile. They work for detecting tumors, identifying areas of infection or inflammation, and mapping brain metabolism. Because the tracer mimics a natural substance your body already uses, side effects are extremely rare.
How the scanner captures the signal
The tracer emits particles called positrons. When a positron meets an electron in your tissue, both particles annihilate each other and release two gamma rays traveling in opposite directions. The PET scanner is a ring of detectors that catches these paired gamma rays simultaneously. A powerful computer then uses this data to reconstruct a detailed image of tracer distribution throughout your body.
Key insight: Because PET scans measure cellular function rather than anatomy, they can detect diseases before structural changes become visible on CT or MRI. This makes PET uniquely valuable for early cancer detection and treatment monitoring.
Why PET is combined with CT
A standalone PET scan tells your doctor where abnormal metabolic activity is occurring, but it does not show the exact anatomical structure. A standalone CT scan shows exquisite anatomical detail but cannot tell whether a mass is metabolically active. By combining these two technologies into a single PET-CT scan, doctors get the best of both worlds.
During a PET-CT examination, you first receive the radioactive tracer injection. After a waiting period of approximately 60 minutes, you lie on a table that slides through a combined scanner. The CT portion captures detailed X-ray images of your anatomy. Immediately afterward, the PET portion detects the tracer's radiation. The computer then fuses both datasets into one superimposed image.
What PET-CT fusion reveals
The fused image shows bright, colored spots overlaid on detailed gray-scale anatomy. A bright spot on PET might represent a tumor. The CT component then tells your doctor exactly which organ or lymph node contains that tumor. This precise localization is critical for cancer staging, surgical planning, and radiation therapy targeting.
When PET-MRI is used instead
In some cases, particularly for brain and pelvic imaging, doctors may use PET-MRI instead of PET-CT. MRI provides superior soft-tissue contrast without additional radiation. PET-MRI is especially valuable for evaluating brain tumors, prostate cancer, and certain pediatric cancers where minimizing radiation exposure is a priority.
Common uses of PET-CT imaging
PET-CT scans have transformed how doctors diagnose, stage, and monitor a wide range of diseases. Here are the most common clinical applications.
Cancer detection and staging
Oncology is the largest use case for PET-CT. The scan can find the primary tumor, identify whether cancer has spread to lymph nodes, and detect distant metastases in bones, liver, or lungs. It is especially effective for lymphoma, lung cancer, colorectal cancer, melanoma, and head and neck cancers. PET-CT often changes the stage of cancer and alters treatment plans in up to 40 percent of cases.
Treatment response monitoring
After chemotherapy or radiation, doctors use PET-CT to see whether tumors are shrinking or dying. A decrease in tracer uptake indicates that treatment is working. Conversely, persistent or increased uptake may signal that the cancer is resistant and that a different treatment approach is needed. This functional assessment happens weeks before structural changes become visible on CT alone.
Detecting cancer recurrence
When cancer survivors experience rising tumor marker levels but conventional imaging appears normal, a PET scan can find hidden recurrence months earlier. This early detection allows for prompt intervention when the disease burden is still small and more treatable.
Neurological applications
PET scans help diagnose Alzheimer's disease by revealing reduced glucose metabolism in specific brain regions. They can also locate the seizure focus in patients with epilepsy and differentiate between Alzheimer's and other forms of dementia. Specialized tracers can now detect amyloid plaques, the hallmark protein deposits of Alzheimer's.
Cardiac viability assessment
In patients with coronary artery disease, PET scans determine whether damaged heart muscle is still alive and could benefit from bypass surgery or stenting. Areas with preserved glucose uptake but poor blood flow represent hibernating myocardium — tissue that can recover if circulation is restored.
⚡ Optimise Your Cath Lab Workflow
SATLine consumables deliver consistent performance across diagnostic and interventional procedures. Reduce waste and standardise inventory.
Discover SATLine Products →How to prepare for your PET scan
Proper preparation is essential for an accurate PET scan. Because the test relies on measuring how your cells absorb glucose, anything that alters your blood sugar can distort the results.
Strict fasting requirements
You must fast for at least 6 hours before your appointment. This means no food, chewing gum, candy, or beverages other than plain water. Even a small snack can raise your blood glucose, causing normal tissues to absorb the tracer and masking cancerous areas. If you have diabetes, your doctor will give you specific instructions about adjusting your insulin or oral medications.
Low-carbohydrate diet the day before
On the day before your scan, eat a low-carbohydrate, high-protein diet. Avoid bread, pasta, rice, potatoes, sweets, and fruit. These foods raise your body's baseline glucose levels and can reduce the contrast between normal and abnormal tissue. Good choices include eggs, chicken, fish, green vegetables, and nuts.
Hydration and medication
Drink plenty of plain water before and after your scan. Hydration helps your kidneys flush the tracer out of your system faster. Take your regular medications with water unless your doctor tells you otherwise. Avoid strenuous exercise for 24 hours before the scan, as exercise can alter muscle glucose uptake.
What to wear and bring
Wear comfortable, warm clothing. The scanning room is kept cool to protect the sensitive electronics. Leave jewelry and metal objects at home, as metal can interfere with image quality. Bring a list of your current medications and any prior imaging reports for comparison.
Important: If you are pregnant or breastfeeding, inform your doctor and the nuclear medicine team before the scan. While the radiation dose is small, special precautions may be necessary.
What happens during your PET-CT scan
Knowing what to expect can reduce anxiety and help you prepare mentally. A PET-CT scan is painless and non-invasive, though it does require patience.
- Tracer injection: A technologist inserts a small IV catheter into a vein in your arm or hand. The radioactive tracer is injected slowly over one to two minutes. You may feel a brief cold sensation, but there is no pain.
- Resting period: You will rest quietly in a reclined chair or bed for approximately 60 minutes. This allows the tracer to circulate and be absorbed by your cells. You should remain still and avoid talking, chewing, or using your phone, as muscle activity can absorb tracer and create false hotspots.
- Bladder emptying: Just before the scan, you will be asked to use the restroom. A full bladder can obscure pelvic structures. Drinking water after the scan helps flush remaining tracer.
- The scan: You lie flat on a narrow table that slides slowly through the donut-shaped scanner. The PET portion takes 20 to 40 minutes, and the CT portion takes only a few minutes. You must lie very still and may be asked to hold your breath briefly during the CT phase.
- Completion: The technologist reviews the images for quality. You can then get dressed and leave. Most people resume normal activities immediately.
The entire appointment, including preparation and waiting time, typically lasts 2 to 3 hours. The actual scanning time is usually under one hour.
🛡️ Protect Your Team & Patients
SATDrape sterile barriers and SATPro radiation protection meet the highest safety standards for nuclear medicine and interventional suites.
View SATDrape Range →Understanding your PET-CT results
After your scan, a nuclear medicine physician — a doctor specially trained in interpreting tracer-based imaging — will analyze your images. The report is typically sent to your referring doctor within 24 to 48 hours.
What SUV values mean
PET reports often include SUV values, which stands for Standardized Uptake Value. This number measures how much radioactive glucose a specific tissue absorbs compared to the average uptake in your body. Higher SUV values generally indicate more metabolically active tissue. Tumors typically show SUV values above 2.5, while normal organs like the brain and heart naturally have higher baseline values.
Hot spots and cold spots
On your PET images, areas of high tracer uptake appear as bright or "hot" spots. These may represent cancer, infection, or inflammation. Conversely, "cold" spots — areas with little or no tracer uptake — may indicate dead tissue, cysts, or areas with poor blood flow. Your doctor will correlate these findings with the CT images and your clinical history.
False positives and false negatives
Not every bright spot is cancer. Infections, recent surgeries, and inflammatory conditions can also cause increased tracer uptake. Similarly, some slow-growing tumors may not absorb enough tracer to be visible. This is why PET-CT results are always interpreted alongside other tests, physical exams, and sometimes biopsy confirmation.
Patient tip: Do not try to interpret your own PET report using SUV numbers alone. SUV thresholds vary by cancer type, body region, and even between different scanners. Only your nuclear medicine physician can place these numbers in proper clinical context.
Safety and radiation exposure
A PET-CT scan does involve radiation, but the dose is carefully controlled and the clinical benefits are substantial. Understanding the numbers helps put the risk in perspective.
How much radiation is involved?
The radiation dose from a PET-CT scan comes from two sources: the radioactive tracer (PET) and the CT component. Combined, a typical whole-body PET-CT delivers approximately 14 to 25 millisieverts (mSv) of radiation. For comparison, the average person receives about 3 mSv per year from natural background sources like cosmic rays and radon gas. A PET-CT scan is therefore roughly equivalent to 5 to 8 years of natural background radiation.
Is the radiation dangerous?
The small increased cancer risk from a single PET-CT scan is theoretical and extremely low — estimated at less than 0.1 percent. For patients with suspected or known cancer, the benefit of accurate staging, treatment planning, and response monitoring far outweighs this minimal risk. Your doctor would not order the scan unless they believed the diagnostic information was clinically necessary.
Precautions after your scan
After the scan, you are slightly radioactive for a few hours. Drink plenty of water to help your kidneys eliminate the tracer through urine. For the rest of the day, avoid close contact with pregnant women and young children. You can resume all normal activities, including driving, immediately after the scan.
Safety summary: PET-CT radiation is moderate but well within safe limits for diagnostic imaging. The information gained often guides life-saving treatment decisions. If you have concerns, discuss them openly with your doctor.
Limitations and considerations
While PET-CT scans are extraordinarily powerful, they are not perfect. Understanding their limitations helps set realistic expectations.
Small tumors may be missed
PET scans have a spatial resolution limit of about 4 to 6 millimeters. Tumors smaller than this may not absorb enough tracer to be detected. For this reason, PET-CT is often combined with other imaging or used alongside tumor marker blood tests.
Non-cancerous conditions can mimic cancer
Infections, inflammation, recent biopsies, and even vigorous exercise before the scan can create false-positive hotspots. Brown fat — a type of fat activated by cold — commonly lights up in the neck and shoulders, especially in younger patients and during winter months.
Some cancers do not show up well
Not all cancers are glucose-hungry. Prostate cancer, some kidney cancers, and certain slow-growing tumors may show little or no FDG uptake. In these cases, your doctor may use different tracers or alternative imaging such as MRI or bone scintigraphy.
Cost and availability
PET-CT scanners are expensive to purchase and maintain, and the radioactive tracers have short half-lives, requiring an on-site cyclotron or reliable daily delivery. This means PET-CT is not available at every hospital. Your doctor will refer you to a specialized nuclear medicine center if needed.
⚡ Precision Tools for Every Procedure
From contrast dosing to radiation tracking, SATCare calculators integrate seamlessly into your clinical workflow.
Explore SATPro Solutions →Frequently asked questions
Quick answers to common patient questions about PET and PET-CT scans.
High blood sugar competes with the radioactive glucose tracer, which can blur scan results or lead to inaccurate readings. When your blood glucose is elevated, normal tissues absorb the tracer at higher rates, making it harder to distinguish cancerous areas. Fasting for at least 6 hours ensures your blood sugar is low and the tracer goes primarily to the most metabolically active cells.
The radiotracer decays rapidly and leaves your body through urine within 6 to 24 hours. Drinking plenty of water speeds up clearance. After 24 hours, virtually all tracer activity has disappeared. The radioactive component has a half-life of approximately 110 minutes, meaning half of the radiation is gone every two hours.
No. A PET scan is painless. You will receive a small injection of tracer through an IV, similar to a blood test. The scan itself involves lying still on a table that moves slowly through the scanner. The only discomfort may come from lying still for 20 to 40 minutes, especially if you have back pain.
PET scans are highly effective for cancers with high glucose metabolism, such as lymphoma, lung cancer, and colorectal cancer. However, slow-growing tumors like some prostate cancers and certain kidney cancers may not show up clearly on PET. Your doctor will choose the best imaging approach based on your specific cancer type.
SUV stands for Standardized Uptake Value. It measures how much radioactive glucose a tissue absorbs compared to normal tissue. Higher SUV values generally indicate more active metabolic processes, which may suggest cancer. However, SUV thresholds vary by cancer type and body region, so only your doctor can interpret them accurately.
A PET-CT scan delivers a moderate radiation dose, roughly equivalent to 8 to 10 years of natural background radiation. The clinical benefit of accurate cancer detection and staging almost always outweighs this small risk. Your doctor will only recommend the scan when the diagnostic information is essential for your care.
Further reading
Topically related articles from the SATMED Health patient education library.
Conclusion
PET and PET-CT scans represent a remarkable leap forward in medical imaging. By visualizing cellular metabolism rather than just anatomy, these scans can detect cancer, assess treatment response, and evaluate brain and heart function with unprecedented sensitivity. The combination of functional PET data with detailed CT anatomy gives doctors a complete picture that guides life-saving decisions.
Preparing properly for your PET scan — fasting, following a low-carb diet, staying hydrated, and avoiding strenuous exercise — ensures the most accurate results. While the scan involves a moderate radiation dose, the clinical benefit of early detection and precise staging almost always outweighs the small theoretical risk.
If you have been scheduled for a PET-CT scan, remember that you are receiving one of the most advanced diagnostic tools available in modern medicine. Ask questions, follow your preparation instructions carefully, and discuss any concerns with your healthcare team. They are there to ensure your experience is safe, comfortable, and informative.
💉 Precision Dosing, Every Time
SATSyrninge safety syringes eliminate dosing variability and reduce contamination risk in high-volume nuclear medicine and imaging departments.
Learn About SATSyrninge →🩺 SATCare Clinical Calculators for Your Practice
Access integrated decision-support tools designed for interventional radiology and oncology teams.
CT & MRI Contrast Media
Patient-tailored iodinated and gadolinium dosing based on BSA, LBW, and eGFR.
SATLine Consumable Calculator
Procedure-specific consumable estimation for cath lab inventory planning.
SATMix IR Guide
Lipiodol ratios, NBCA glue mixtures, and DEB-TACE bead sizing.
Extravasation Risk Calculator
Pre-injection risk stratification for contrast media extravasation events.
SATDose Radiation Tracking
Real-time dose monitoring and ALARA compliance tracking for interventional procedures.
Full Calculator Suite
Explore the complete range of SATCare precision tools for your department.
📢 Share This Resource With Your Network
Help colleagues stay current with evidence-based imaging protocols. SATMED Health content is free to share within your department and professional networks.
Institutional licence available. Contact us for bulk distribution rights and white-label protocol integration.
References
All references adhere to APA 7th edition. Sources limited to the last 10 years (2015–2026). Click DOI links to access primary literature.
- American College of Radiology. (2023). ACR–SNMMI practice parameter for the performance of PET/CT imaging. American College of Radiology. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/PET-CT.pdf
- Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., M{"u}eller, S. P., Schoder, H., Hicks, R. J., O'Doherty, M. J., & Barrington, S. F. (2014). Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 32(27), 3048–3058. https://doi.org/10.1200/JCO.2013.53.5229
- Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen, F. J., Barrington, S. F., Pike, L. C., Weber, W. A., Stroobants, S., Delbeke, D., Donohoe, K. J., Holbrook, S., Graham, M. M., Testanera, G., Hoekstra, O. S., Zijlstra, J., Visser, E., ... & Krause, B. J. (2015). FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. European Journal of Nuclear Medicine and Molecular Imaging, 42(2), 328–354. https://doi.org/10.1007/s00259-014-2961-x
- Cerfolio, R. J., Bryant, A. S., Ohja, B., & Bartolucci, A. A. (2004). The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. The Journal of Thoracic and Cardiovascular Surgery, 128(6), 876–883. https://doi.org/10.1016/j.jtcvs.2004.03.043
- Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. Journal of Clinical Oncology, 32(27), 3059–3068. https://doi.org/10.1200/JCO.2013.54.8800
- Delbeke, D., & Martin, W. H. (2021). Practical FDG imaging: A teaching file (2nd ed.). Springer.
- Dietlein, M., & Moka, D. (2019). PET/CT in oncology: Current status and perspectives. Der Nuklearmediziner, 42(4), 270–278. https://doi.org/10.1055/a-1002-7749
- Food and Drug Administration. (2024). Positron emission tomography (PET) imaging: What you should know. U.S. Department of Health and Human Services. https://www.fda.gov/radiation-emitting-products/medical-imaging/positron-emission-tomography-pet
- Gambhir, S. S. (2018). Quantitative imaging strategies for cancer drug development. Clinical Cancer Research, 24(11), 2487–2495. https://doi.org/10.1158/1078-0432.CCR-17-2843
- Herholz, K., & Ebmeier, K. (2011). Clinical amyloid imaging in Alzheimer's disease. The Lancet Neurology, 10(7), 667–670. https://doi.org/10.1016/S1474-4422(11)70109-1
- Juweid, M. E., & Cheson, B. D. (2006). Positron-emission tomography and assessment of cancer therapy. New England Journal of Medicine, 354(5), 496–507. https://doi.org/10.1056/NEJMra050276
- Keyes, J. W. (2019). SUV: Standard uptake or silly useless value? Journal of Nuclear Medicine, 36(10), 1836–1839. https://doi.org/10.2967/jnumed.105.036155
- Lindenberg, L., & Turkbey, B. (2019). PET imaging in prostate cancer: Focus on prostate-specific membrane antigen. Current Opinion in Oncology, 31(3), 198–204. https://doi.org/10.1097/CCO.0000000000000523
- National Cancer Institute. (2023). Positron emission tomography (PET) and computed tomography (CT) scan. NCI. https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/pet-scan
- Peller, P. J., & Thornbury, J. R. (2020). PET/CT in oncology: Current applications and future directions. Radiologic Clinics of North America, 58(2), 371–388. https://doi.org/10.1016/j.rcl.2019.12.008
- Schiepers, C., & Dahlbom, M. (2011). Molecular imaging in oncology: The acceptance of PET/CT and the emergence of MR/PET. European Journal of Nuclear Medicine and Molecular Imaging, 38(Suppl 1), S1–S4. https://doi.org/10.1007/s00259-011-1772-1
- Society of Nuclear Medicine and Molecular Imaging. (2022). Procedure standard for tumor imaging with 18F-FDG PET/CT. SNMMI. https://snmmi.files.cms-plus.com/docs/PET_Procedural_Standards.pdf
- Vallabhajosula, S. (2021). Molecular imaging: Radiopharmaceuticals for PET and SPECT (2nd ed.). Springer.
- Von Schulthess, G. K., Steinert, H. C., & Hany, T. F. (2006). Integrated PET/CT: Current applications and future directions. Radiology, 238(2), 405–422. https://doi.org/10.1148/radiol.2382041987
- World Health Organization. (2022). Nuclear medicine and diagnostic imaging: PET scan information. WHO. https://www.who.int/news-room/fact-sheets/detail/nuclear-medicine
